RESUMO
The effect of human placental lactogen (hPL), a member of the somatomammotrophin family, on the regulation of the scavenger receptor molecules CD14 and CD163 on human monocytes cultured for 48h was investigated. Cells were cultured in the presence or absence of the hormone and also in the presence or absence of IFN-gamma and dexamethasone. Monocytes cultured in the presence of hPL showed a significant increase in the expression of CD14 in both males and females compared to background. When IFN-gamma and dexamethasone were added to the cultures, CD14 expression was decreased and was not rescued by the presence of hPL. hPL alone had no effect on the expression of CD163 on cultured monocytes from either gender, although cells cultured in the presence of IFN-gamma and dexamethasone showed a profound increase in their expression of CD163. This expression was augmented further by the presence of hPL in the cultures over a 48-h period. These results support the hypothesis of a potential role of this hormone in the regulation of the innate immune response.
Assuntos
Antígenos CD , Antígenos de Diferenciação Mielomonocítica/biossíntese , Receptores de Lipopolissacarídeos/biossíntese , Monócitos/metabolismo , Lactogênio Placentário/farmacologia , Receptores de Superfície Celular/biossíntese , Anti-Inflamatórios/imunologia , Anti-Inflamatórios/farmacologia , Antígenos de Diferenciação Mielomonocítica/imunologia , Células Cultivadas , Dexametasona/imunologia , Dexametasona/farmacologia , Feminino , Humanos , Imunidade Inata , Interferon gama/imunologia , Interferon gama/farmacologia , Receptores de Lipopolissacarídeos/imunologia , Masculino , Monócitos/imunologia , Lactogênio Placentário/imunologia , Receptores de Superfície Celular/imunologiaRESUMO
To confirm that concomitant administration of aminoglutethimide (AG) reduces plasma levels of medroxyprogesterone acetate (MPA), MPA levels were assayed in six patients with advanced breast cancer receiving the two agents. Patients had disease resistant to AG and were studied during conversion to therapy with MPA. Hydrocortisone was discontinued at the commencement of study and MPA introduced and given at a constant dose of 800 mg daily while AG was reduced in dose from 250 mg b.d. to 125 mg b.d. and then discontinued. MPA levels were measured after two weeks at each dose of AG and after two weeks on MPA alone. Mean MPA levels showed a progressive and significant (P less than 0.01) rise as the AG dose was reduced--180 ng ml-1, 250 ng ml-1 and 740 ng ml-1 respectively. MPA levels were always in excess of the accepted therapeutic level of 100 ng ml-1 and plasma cortisol levels fell in parallel with the rise in MPA levels.
